Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis (Q34627112)

3 August 2017

title

Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis (English)

1 reference

3 August 2017

0 references

1 reference

2

A S Lacasce

1 reference

3 August 2017

J A Barnes

1

1 reference

3 August 2017

Y Feng

3

1 reference

3 August 2017

C E Toomey

4

1 reference

3 August 2017

D Neuberg

5

1 reference

3 August 2017

J S Michaelson

6

1 reference

3 August 2017

E P Hochberg

7

1 reference

3 August 2017

J S Abramson

8

1 reference

3 August 2017

publication date

21 February 2011

1 reference

3 August 2017

1 reference

3 August 2017

volume

22

1 reference

3 August 2017

issue

8

1 reference

3 August 2017

page(s)

1859-1864

1 reference

3 August 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ677

Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ677

An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ677

Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ677

A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ677

High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ677

Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ677

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ677

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ677

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ677

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ677

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ677

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ677

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ677

Molecular diagnosis of Burkitt's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ677

A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ677

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ677

1 reference

3 August 2017

1 reference